loading
Precedente Chiudi:
$1.07
Aprire:
$1.06
Volume 24 ore:
684.46K
Relative Volume:
0.33
Capitalizzazione di mercato:
$17.53M
Reddito:
-
Utile/perdita netta:
$-11.90M
Rapporto P/E:
-0.0057
EPS:
-206.0125
Flusso di cassa netto:
$-12.75M
1 W Prestazione:
+16.06%
1M Prestazione:
+10.58%
6M Prestazione:
-25.81%
1 anno Prestazione:
-16.67%
Intervallo 1D:
Value
$1.0599
$1.17
Intervallo di 1 settimana:
Value
$0.953
$1.19
Portata 52W:
Value
$0.1131
$3.95

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name
Nome
Allarity Therapeutics Inc
Name
Telefono
401-426-4664
Name
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Name
Dipendente
7
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ALLR's Discussions on Twitter

Confronta ALLR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALLR
Allarity Therapeutics Inc
1.165 17.53M 0 -11.90M -12.75M -206.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
506.33 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.17 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
631.43 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.70 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
247.88 24.70B 3.81B -644.79M -669.77M -6.24

Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie

pulisher
11:33 AM

The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com

11:33 AM
pulisher
07:34 AM

Upward Trajectory: Allarity Therapeutics Inc (ALLR) Posts a Slidee, Closing at 1.07 - DWinneX

07:34 AM
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 25, 2025

Allarity unveils new multiple myeloma treatment predictor - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 23, 2025

Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

How to interpret Allarity Therapeutics Inc (ALLR)’s stock chart patterns - uspostnews.com

Apr 22, 2025
pulisher
Apr 21, 2025

Allarity Therapeutics Inc (ALLR) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 21, 2025
pulisher
Apr 16, 2025

Allarity Therapeutics Restructures Board of Directors - TipRanks

Apr 16, 2025
pulisher
Apr 14, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire

Apr 14, 2025
pulisher
Apr 10, 2025

Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com

Apr 10, 2025
pulisher
Apr 09, 2025

Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News

Apr 08, 2025
pulisher
Apr 08, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 04, 2025

Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister

Apr 04, 2025
pulisher
Apr 03, 2025

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics Inc. (ALLR) reports earnings - qz.com

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter

Mar 31, 2025
pulisher
Mar 26, 2025

Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics probes potential stock manipulation - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan

Mar 24, 2025
pulisher
Mar 20, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM

Mar 19, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity reports promising ovarian cancer trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 17, 2025

Can you now get a good deal on Allarity Therapeutics Inc’s shares? - uspostnews.com

Mar 17, 2025
pulisher
Mar 14, 2025

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com

Mar 14, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener

Mar 13, 2025

Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Capitalizzazione:     |  Volume (24 ore):